Aim/hypothesis MicroRNA-9 (miR-9) is involved in the regulation of pancreatic beta cell function. However, its role in gluconeogenesis is still unclear. Our objective was to investigate the role of miR-9 in hepatic glucose production (HGP). Methods MiR-9 expression was measured in livers of high-fat diet (HFD) mice and ob/ob mice. The methylation status of the miR-9-3 promoter regions in hepatocytes was determined by the methylation-specific PCR procedure. The binding activity of DNA methyltransferase (DNMT)1, DNMT3a and DNMT3b on the miR-9-3 promoter was detected by chromatin immunoprecipitation (ChIP) and quantitative real-time PCR assays. HGP was evaluated in vitro and in vivo. Glucose tolerance, insulin tolerance and pyruvate tolerance tests were also performed. Results Reduced miR-9 expression and hypermethylation of the miR-9-3 promoter were observed in the livers of obese mice. Further study showed that the binding of DNMT1, but not of DNMT3a and DNMT3b, to the miR-9-3 promoter was increased in hepatocytes from ob/ob mice. Knockdown of DNMT1 alleviated the decrease in hepatic miR-9 expression in vivo and in vitro. Overexpression of hepatic miR-9 improved insulin sensitivity in obese mice and inhibited HGP. In addition, deletion of hepatic miR-9 led to an increase in random and fasting blood glucose levels in lean mice. Importantly, silenced forkhead box O1 (FOXO1) expression reversed the gluconeogenesis and glucose production in hepatocytes induced by miR-9 deletion. Conclusions/interpretation Our observations suggest that the decrease in miR-9 expression contributes to an inappropriately activated gluconeogenesis in obese mice.
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Introduction
The liver is a key organ for maintaining glucose homeostasis in the body through insulin-and other metabolic hormonemediated events [1, 2] . However, in diabetic patients with insulin resistance (IR), insulin fails to effectively inhibit gluconeogenic pathways, which results in an increase in hepatic glucose production (HGP) [3] . In addition, inappropriately elevated glucagon also increases HGP by promoting the expression and activity of gluconeogenic enzymes [4] . Therefore, elucidation of the underlying molecular mechanism of gluconeogenesis as well as HGP is of potential benefit for the development of effective therapies for the treatment of IR and type 2 diabetes. The transcription factor forkhead box O1 (FOXO1) is implicated in multiple metabolic pathways [5] . In the liver, FOXO1 promotes HGP and activates the transcription of gluconeogenic enzymes, such as glucose-6-phosphatase (G6Pase) and PEPCK [6, 7] . Increased FOXO1 expression was observed in patients with hepatic IR and nuclear FOXO1 was significantly accumulated in the livers of highfat diet (HFD) mice and db/db mice [8, 9] . Further study demonstrated that overexpression of FOXO1 led to an increase in gluconeogenesis and HGP [10] . In contrast, deletion of hepatic FOXO1 in diabetic mice improved insulin sensitivity and glucose tolerance [11, 12] . These studies indicated that FOXO1 acts as a regulator and mediator in the development of IR and type 2 diabetes [13] , but the mechanism by which molecular factors regulate hepatic FOXO1 expression and activity during IR remains elusive.
MicroRNAs (miRs), a class of small non-coding RNAs, regulate target gene expression at the post-transcriptional level [14] . Growing evidence demonstrates that aberrant expression of miRs contributes to a variety of human diseases, including diabetes [15] . Recently, some studies have revealed a few miRs, notably miR-29a-c and miR-23a, are critical for gluconeogenesis [16, 17] . Li demonstrated that miR-214 could suppress gluconeogenesis by directly targeting activating transcription factor 4 (ATF4), which affected FOXO1 transcriptional activity [18] . One particular miR, miR-9, has been discovered to be involved in the development of type 2 diabetes, based on evidence that miR-9 plays an important role in the regulation of in vitro and in vivo insulin secretion [19, 20] . However, the effect of miR-9 on IR has not yet been investigated. Interestingly, FOXO1 has been confirmed as the direct target of miR-9 in haematopoietic cells [21] . Consequently, miR-9 might be involved in the regulation of insulin sensitivity in diabetes mellitus.
Recent research has shown that epigenetic DNA modifications contribute to the development of type 2 diabetes [22, 23] . Environmental factors, such as excess nutrition, can affect epigenetic regulation [24] . One of the major epigenetic mechanisms is DNA methylation, which has also been shown to be important in insulin sensitivity [25, 26] . DNA methylation leads to a decrease in gene transcription by inhibiting the binding of transcriptional factors to gene promoters [27] . We have found that miR-9 is significantly downregulated in the liver of HFD mice and ob/ob mice. We also found specific inhibition of DNA methylation could upregulate miR-9 expression in hepatocytes. We therefore hypothesised that epigenetic regulation might be involved in the regulation of miR-9 expression in the livers of obese mice. We tested this hypothesis using HepG2 cells, primary hepatocytes, HFD-fed mice and ob/ob mice.
Methods
Reagents See electronic supplementary material (ESM) Methods.
Cell culture The human hepatoblastoma cell line HepG2 was purchased from ATCC (Rockville, MD, USA) and cultured in DMEM supplemented with 10% (vol./vol.) FBS. HepG2 cells were cultured at 37°C in a humidified atmosphere containing 95% air and 5% CO 2 . All cells were verified in our laboratory and there was no mycoplasma contamination.
Primary isolation and culture of hepatocytes Hepatocytes were isolated and cultured from the livers of male C57BL/6J mice as described previously [28] . For further details, please refer to the ESM Methods.
Animal studies All animal studies were performed following the guideline established by the Research Animal Care Committee of Nanjing Medical University (Nanjing, China). Male C57BL/6J mice and 8-to 10-week-old male ob/+ or ob/ ob mice were purchased from the Model Animal Research Center of Nanjing University (Nanjing, China). Diet-induced obese mice were fed ad libitum an HFD (D12492; Research Diets, New Brunswick, NJ, USA) for 15 weeks. Mice were housed under 12/12 h light/dark cycles with free access to food and water. C57BL/6J mice were injected with normal control (NC) or miR-9 inhibitor, and ob/ob mice were injected with NC or miR-9 mimic when they were 8 weeks old. HFD-fed mice were injected with NC or miR-9 mimic when they were fed an HFD for 11 weeks. Mice were injected i.v. through the tail vein with a lipid nanoparticle-formulated miR-9 inhibitor or miR-9 mimic, at a dose of 100 nmol in 0.2 ml PBS, as described previously [29] . The DNA methyltransferase (DNMT) inhibitor was injected into ob/+ or ob/ob mice as described previously [30] . The ob/ob mice were also i. ) daily for 5 weeks. The experimenters were not blind to group assignment and outcome assessment.
Real-time PCR assay The expression of mRNA and microRNA was quantified by real-time PCR using a LightCycler480 II Sequence Detection System (Roche, Basel, Switzerland). For further details, please refer to the ESM Methods.
Western blot analysis Total protein was isolated from HepG2 cells, primary mouse hepatocytes and liver tissue from mice. For further details, please refer to the ESM Methods.
DNA methylation analyses Genomic DNA was subjected to sodium bisulphite treatment using Methylamp (Epigentek, Brooklyn, NY, USA). The methylation status of the miR-9-3 promoter regions in hepatocytes was measured by methylationspecific PCR (MSP). Bisulphite genomic sequencing analyses were determined as previously described [31] . Quantitative MSP (qMSP) for the miR-9-3 promoter was performed using a real-time PCR assay as previously described [32] . For further details, please refer to the ESM Methods.
Chromatin immunoprecipitation assays and chromatin immunoprecipitation-quantitative PCR assay Chromatin immunoprecipitation (ChIP) and ChIP-quantitative real-time PCR (ChIP-qPCR) assays were performed using lysates of hepatocytes as described previously [33] . For further details, please refer to the ESM Methods.
Oligonucleotides and cell transfection MiR-9 was downregulated or upregulated by transfection with a miR-9 inhibitor or miR-9 mimic, respectively, using Lipofectamine 2000 (Invitrogen Life Technologies, Grand Island, NY, USA) according to the manufacturer's recommendations. All oligonucleotides were transfected at a final concentration of 100 nmol/l. For further details, please refer to the ESM Methods.
Small interfering RNA Small interfering RNAs (siRNAs) specific for FOXO1 (si-Foxo1) and control siRNA (si-NC) were synthesised (Ribobio, Guangzhou, China) and transfected using Lipofectamine 2000 into HepG2 cells. The sequences of si-Foxo1 and all other siRNAs are available in ESM Table 1 .
Glucose tolerance test, insulin tolerance test and pyruvate tolerance test The glucose tolerance test (GTT) was performed by an i.p. injection of D-glucose (2 g/kg body weight, i.p.) after a 16 h overnight fast. Blood glucose levels were measured at 0, 30, 60, 90 and 120 min after injection. The insulin tolerance test (ITT), mice were fasted for 6 h and then injected with human insulin (Novo-Nordisk, Bagsvaerd, Denmark) at 0.75 U/kg body weight. Blood glucose levels were measured at 0, 15, 30, and 60 min. A pyruvate tolerance test (PTT) was performed to estimate gluconeogenesis. Mice were starved for 16 h and then injected i.p. with pyruvate (2 g/kg body weight, i.p.) dissolved in saline (154 mmol/l NaCl). Blood glucose levels were measured in the tail blood every 30 min for 2 h. Blood glucose levels were measured using the hexokinase method (Thermo Fisher Scientific, Lafayette, CO, USA). Serum insulin levels were determined using an insulin ELISA kit (Lynco Research, St Charles, MO, USA).
Statistical analysis Statistical analyses were performed using SPSS 13.0 statistical analysis software (SPSS, Chicago, IL, USA). Data were expressed as the mean ± SD. Analysis of variance (ANOVA) was used to determine the statistical differences among the groups. A p value <0.05 was considered statistically significant. Results are representative of three individual experiments. No data, samples or animals were excluded or omitted from reporting.
Results
Hepatic miR-9 expression is decreased in obese mice and in normal mice under fasting conditions We evaluated the role of miR-9 in IR by determining the relative expression of miR-9 in two different obese mouse models. First, we found that the expression of mature miR-9 was clearly inhibited in livers from obese mice fed an HFD when compared with lean mice fed a normal chow diet (NCD) (Fig. 1a) . Since mature miR-9 is encoded in mammals by three genes (miR-9-1, miR-9-2 and miR-9-3), we next measured the expression of miR-9-1, miR-9-2 and miR-9-3. The level of miR-9-3 was significantly reduced in the HFD-fed mice, while the levels of miR-9-1 and miR-9-2 were not altered (Fig. 1b-d) . Next, we observed a significant decrease in mature miR-9 and miR-9-3 expression in livers from ob/ob obese mice when compared with expression in wild-type mouse livers (Fig. 1e, f) . In addition, we measured hepatic miR-9 expression levels in C57BL/6J normal mice, following a 16 h fast. Interestingly, fasting reduced the miR-9 expression (Fig. 1g) . We demonstrated, among the three isoforms of miR-9, that the level of miR-9-3 was the most highly expressed, followed by miR-9-1 and miR-9-2 in primary hepatocytes isolated from C57BL/6J normal mice, which was confirmed by gel electrophoresis (ESM Fig. 1 ).
DNA hypermethylation reduces hepatic miR-9 expression
We next investigated if epigenetic DNA modification was a contributor to the silencing of miR-9 expression in our system by first treating cells with 5-Aza-CdR, a specific inhibitor of DNA methylation, and with trichostatin A (TSA), a histone deacetylase inhibitor. We found that 5-Aza-CdR significantly upregulated mature miR-9 expression in HepG2 cells and primary hepatocytes (Fig. 2a) . However, TSA had no effect on miR-9 expression (Fig. 2b) .
Interestingly, the miR-9-3 promoter was highly methylated in hepatocytes from HFD-fed mice when compared with those from NCD-fed mice. Likewise, the miR-9-3 promoter was hypermethylated in hepatocytes from ob/ob mice (Fig. 2c) . The qMSP results confirmed that the methylation of the miR-9-3 promoter was significantly increased in hepatocytes from HFD-fed and ob/ob mice (Fig. 2d) . However, methylation of the miR-9-1 and miR-9-2 promoter was not significantly increased in hepatocytes from HFD-fed and ob/ob mice compared with that in the lean mice (ESM Fig. 2 ).
DNMT1 governs hepatic miR-9 levels in ob/ob mice DNA methylation is catalysed by DNA methyltransferase enzymes, which include DNMT1, DNMT3a and DNMT3b [34] . Quantitative ChIP (qChIP) assays demonstrated the association of DNMT1, DNMT3a and DNMT3b with the miR-9-3 promoter region. The binding of DNMT1, but not DNMT3a and DNMT3b, onto the promoters of miR-9-3 was increased in hepatocytes from ob/ob mice when compared with those from lean mice (Fig. 3a-c) . The DNMT inhibitor RG108, when i.p. injected into ob/ob mice, had no effect on body weight, liver function or mortality (data not shown), but induced an obvious increase in miR-9 expression in the liver when compared with the expression in vehicle-injected ob/ob mice (Fig. 3d) . Relative miR-9-3 level (fold) Relative miR-9 level (fold) Relative miR-9-3 level (fold)
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Relative miR-9-1 level (fold) Relative miR-9-2 level (fold) Fig. 1 Hepatic miR-9 expression is decreased in obese mice and in normal mice under fasting conditions. (a) Expression of mature miR-9 was measured in livers of lean mice fed an NCD and obese mice fed an HFD (n = 3 per group). Expression of miR-9-1 (b), miR-9-2 (c) and miR-9-3 (d) was measured in livers of NCD-fed and HFD-fed mice (n = 3 per group). Expression of mature miR-9 (e) and miR-9-3 (f) was measured in livers of ob/+ and ob/ob mice (n = 3 per group). Expression of mature miR-9 (g) was measured in livers of fasted C57BL/6J normal mice (mice were fasted for 16 h) and fed C57BL/6J normal mice (n = 3 per group). **p < 0.01 vs control mice or ob/+ mice
NCD HFD ob/ob
Methylation level (%) We also measured the effect of DNMT1 deletion on miR-9 expression in ob/ob mice. The miR-9 level was significantly increased in hepatocytes from ob/ob mice following injection of si-Dnmt1 (Fig. 3e) . Western blot data demonstrated that siDnmt1-1 and si-Dnmt1-2 silenced DNMT1 protein levels in hepatocytes from ob/ob mice (Fig. 3f) . These results indicated that DNMT1 decreased miR-9 expression through enhancement of promoter methylation.
Knockdown of DNMT1 alleviates the palmitate-induced decrease of miR-9 expression in vitro We examined the potential involvement of DNMT1 in the in vitro expression of miR-9. Treatment of primary mouse hepatocytes with palmitate significantly decreased miR-9 expression while clearly increasing miR-9-3 promoter methylation. These effects could be rescued by deletion of DNMT1 (Fig. 4a, b) . DNMT1 knockdown led to a significant decrease in DNMT1 binding to the miR-9-3 promoter in palmitateexposed hepatocytes (Fig. 4c) .
Overexpression of hepatic miR-9 suppresses gluconeogenesis in obese mice We investigated whether the increase in miR-9 expression in obese mice livers has any effect on glycaemic control in obese mice. In the HFD-fed mice, upregulation of miR-9 expression in the liver decreased the random and fasting blood glucose levels (Fig. 5a ). The PTT results showed that miR-9 overexpression in the liver significantly decreased the conversion of pyruvate to glucose in the HFD-fed mice, suggesting a decrease in gluconeogenesis (Fig. 5b) . Interestingly, the GTT results showed that increased hepatic miR-9 expression improved glucose tolerance in HFD mice (Fig. 5c) . The ITT results also indicated that miR-9 overexpression improved insulin sensitivity (Fig. 5d) . Gene expression analysis showed a significant increase of miR-9 expression (Fig. 5e) , and a significant decrease of FOXO1, PEPCK and G6Pase protein levels (Fig. 5f ) in the isolated hepatocytes from HFD-fed mice with miR-9 overexpression. Similar results were also obtained in miR-9-overexpressing ob/ob mice (ESM Fig. 3a-c) . These results indicated that miR-9 acted as a regulator of hepatic gluconeogenesis and glycaemic control in vivo.
Deletion of hepatic miR-9 leads to an increase of fasting blood glucose levels in lean mice We further investigated whether hepatic miR-9 affects insulin sensitivity by injecting an miR-9 inhibitor into C57BL/6J mice via the tail vein, as previously described [29] . Figure 6a shows that the miR-9 inhibitor significantly decreased miR-9 expression in hepatocytes. Deletion of hepatic miR-9 also elevated random and fasting blood glucose levels (Fig. 6b) . The PTT results showed that downregulation of miR-9 expression increased the conversion of pyruvate to glucose in lean mice (Fig. 6c) . The GTT data showed impairment of glucose tolerance in response to decreased miR-9 expression in lean mouse livers (Fig. 6d) , while the ITT data indicated suppression of systemic insulin sensitivity (Fig. 6e) . In addition, inhibition of miR-9 expression led to a significant increase in the protein levels of FOXO1, PEPCK and G6Pase (Fig. 6f) .
MiR-9 suppresses gluconeogenesis and HPG by directly targeting FOXO1
The transcription factor FOXO1 is a regulator of gluconeogenesis and is a target of miR-9 in haematopoietic cells and neural cells [21, 35] . We investigated whether FOXO1 is required for the miR-9 inhibition of gluconeogenesis and glucose output. Primary hepatocytes were transfected with miR-9 inhibitor and si-NC or si-Foxo1. Figure 7a shows a significant elevation of FOXO1 expression in cells transfected with miR-9 inhibitor; this effect was reversed by transfection with si-Foxo1. The increases of PEPCK and G6Pase expression by miR-9 deletion were partially abolished in hepatocytes by silencing of FOXO1 expression (Fig. 7b) . FOXO1 knockdown completely reversed the glucose production in hepatocytes treated with miR-9 inhibitor ) for 5 weeks (n = 7 for each group). The expression of miR-9 was measured in hepatocytes from ob/ ob mice. The ob/ob mice were injected with si-NC, si-Dnmt1-1 and siDnmt1-2 daily for 30 days via the tail vein and then miR-9 (e) and DNMT1-1 (f) expression in the liver was determined (n = 7 for each group). **p < 0.01 vs ob/+ mice or vehicle or si-NC (Fig. 7c) . These data suggested that miR-9 inhibited gluconeogenesis and glucose production by regulating FOXO1.
Discussion
Growing evidence now indicates that miRs play key roles in the development of IR and diabetes [36] . This study revealed, for the first time, that reduced hepatic miR-9 levels contribute to gluconeogenesis and IR in HFD mice and ob/ob mice. MiR-9 may have alternative and non-overlapping functions in different cell types. In pancreatic beta cells, miR-9 has been proposed to negatively regulate insulin secretion [20] . MiR-9 acted as an oncogene in leukaemia [37] , but as a tumour suppressor in hepatocellular carcinoma [38] . It is worth mentioning that we have not observed significant differences in body weight, plasma alanine transaminase (ALT) and aspartate transaminase (AST) levels and mortality of mice injected with miR-9 inhibitor or miR-9 mimic compared with mice injected with NC (data not shown). This indicated that miR-9 might play a direct role in suppression of glucose production in liver. Therefore, enhancing hepatic miR-9 expression may be a potential pharmacological strategy to improve insulin sensitivity.
MiR-9 has been found to be relevant to the differentiation of normal hepatocytes [39] . Data from the present study show that miR-9 expression was significantly decreased in obese mouse livers. In mice and humans, mature miR-9 is encoded by three genes: miR-9-1, miR-9-2 and miR-9-3. Here, we demonstrated that, of these, miR-9-3 is the one predominantly expressed in hepatocytes. Interestingly, a decrease in miR-9-3 expression was also observed in the obese mouse liver. Taken together, these data suggest that miR-9-3 is specifically inactivated in the fatty liver, resulting in downregulation of mature miR-9 expression in the obese mouse liver.
How miR-9 is deregulated in the obese mouse liver is not clear. Previous studies reported that DNA methylation is involved in regulating miR-9 expression in haematopoietic cells PTT was performed in mice fasted for 16 h (n = 7 per group; NC, white triangles; miR-9 mimic, black triangles). (c) GTT was performed in mice fasted for 16 h (n = 7 per group; NC, white triangles; miR-9 mimic, black triangles). (d) ITT was performed in mice fasted for 4 h (n = 7 per group; NC, white triangles; miR-9 mimic, black triangles). (e) The expression of miR-9 in hepatocytes from HFD-fed mice was measured (n = 3 per group). (f) The protein levels of FOXO1, PEPCK and G6Pase were determined (n = 3 per group; NC, white bars; miR-9 mimic, black bars).
Values are means ± SD and are representative of three individual experiments. *p < 0.05, **p < 0.01 vs NC group [21] . Here we showed that hepatocytes isolated from HFD-fed and ob/ob mice show an increase in DNA methylation at the miR-9 promoter, concomitantly with the enhanced accumulation of DNMT1 in the miR-9-3 promoter. More importantly, the DNMT1 inhibitor reversed the decrease in miR-9 expression in hepatocytes from obese mice. In addition, silencing of DNMT1 alleviated the palmitate-induced decrease in miR-9 expression in primary mouse hepatocytes. Collectively, these findings clearly demonstrated a role for DNA methylation in regulating obesity-induced downregulation of hepatic miR-9 expression. One question that arises from our results is the precise genes that are regulated by miR-9. The transcription factor FOXO1 has been identified as a target of miR-9 in haematopoietic cells and neural cells [21, 35] . We found that a miR-9 mimic significantly inhibited the activity of the 3′-untranslated region of Foxo1 mRNA and FOXO1 expression in mouse liver cells (data not shown). Given that FOXO1 is an important regulator of hepatic gluconeogenesis [6, 7] , we further speculated that FOXO1 mediates miR-9 function in the regulation of gluconeogenesis and HGP in hepatocytes. This speculation was supported by the observation that silencing of FOXO1 expression could almost completely reverse the increase in gluconeogenic enzyme expression and the glucose output in hepatocytes induced by miR-9 deletion.
In conclusion, our study demonstrates that DNA hypermethylation contributes to downregulation of miR-9 expression in the obese mouse liver, leading to upregulation of FOXO1 expression, and finally to inappropriately activated gluconeogenesis. These findings provide valuable insights into the molecular mechanisms responsible for glucose intolerance and IR. 
